Drug Profile
Recombinant Timothy grass pollen allergoids - Allergopharma
Alternative Names: High-dose rPhleum; rPhleumLatest Information Update: 27 Aug 2019
Price :
$50
*
At a glance
- Originator Biomay
- Developer Allergopharma
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Grass pollen hypersensitivity; Seasonal allergic rhinitis
Most Recent Events
- 27 Aug 2019 No development reported - Phase-III for Grass pollen hypersensitivity (In adolescents, In adults) in United Kingdom, Germany (SC) (Allergopharma pipeline, August 2019)
- 27 Aug 2019 No development reported - Phase-III for Grass pollen hypersensitivity (In adults) in Italy, Germany (SC) (Allergopharma pipeline, August 2019)
- 27 Aug 2019 No development reported - Phase-III for Seasonal allergic rhinitis (In adolescents, In adults) in Germany, Poland, France, Spain, United Kingdom (SC) (Allergopharma pipeline, August 2019)